Pfizer Inc. (PFE) Stake Lowered by Summit Financial Wealth Advisors LLC

Summit Financial Wealth Advisors LLC decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 11.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 133,288 shares of the biopharmaceutical company’s stock after selling 17,711 shares during the quarter. Pfizer accounts for 1.9% of Summit Financial Wealth Advisors LLC’s portfolio, making the stock its 11th largest position. Summit Financial Wealth Advisors LLC’s holdings in Pfizer were worth $5,818,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in Pfizer by 1.5% during the third quarter. Vanguard Group Inc. now owns 441,792,969 shares of the biopharmaceutical company’s stock worth $19,469,816,000 after purchasing an additional 6,620,749 shares in the last quarter. Vanguard Group Inc increased its position in Pfizer by 1.5% in the 3rd quarter. Vanguard Group Inc now owns 441,792,969 shares of the biopharmaceutical company’s stock valued at $19,469,816,000 after buying an additional 6,620,749 shares in the last quarter. Bank of New York Mellon Corp increased its position in Pfizer by 3.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 70,231,649 shares of the biopharmaceutical company’s stock valued at $3,095,110,000 after buying an additional 2,497,736 shares in the last quarter. Morgan Stanley increased its position in Pfizer by 2.1% in the 3rd quarter. Morgan Stanley now owns 55,493,846 shares of the biopharmaceutical company’s stock valued at $2,445,614,000 after buying an additional 1,126,612 shares in the last quarter. Finally, Fisher Asset Management LLC increased its position in Pfizer by 3.3% in the 4th quarter. Fisher Asset Management LLC now owns 41,830,709 shares of the biopharmaceutical company’s stock valued at $1,825,910,000 after buying an additional 1,352,978 shares in the last quarter. Hedge funds and other institutional investors own 67.06% of the company’s stock.

In other Pfizer news, major shareholder Pfizer Inc bought 50,000 shares of the business’s stock in a transaction dated Monday, May 13th. The shares were purchased at an average price of $17.00 per share, for a total transaction of $850,000.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Alexander R. Mackenzie sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $42.83, for a total value of $642,450.00. Following the completion of the transaction, the insider now owns 124,994 shares in the company, valued at approximately $5,353,493.02. The disclosure for this sale can be found here. Insiders have sold a total of 288,726 shares of company stock valued at $12,534,617 in the last quarter. Company insiders own 0.09% of the company’s stock.

A number of analysts recently commented on PFE shares. Citigroup reaffirmed a “neutral” rating and issued a $41.00 target price on shares of Pfizer in a research report on Wednesday, February 20th. Credit Suisse Group reaffirmed a “buy” rating and issued a $48.00 target price on shares of Pfizer in a research report on Monday, May 6th. UBS Group lowered Pfizer from a “buy” rating to a “neutral” rating in a research report on Wednesday, January 23rd. Argus raised Pfizer from a “hold” rating to a “buy” rating and set a $55.00 target price for the company in a research report on Thursday, January 31st. Finally, JPMorgan Chase & Co. set a $46.00 target price on Pfizer and gave the company a “neutral” rating in a research report on Tuesday, April 30th. Fourteen research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Pfizer presently has an average rating of “Hold” and an average target price of $45.83.

PFE stock traded down $0.11 during mid-day trading on Thursday, reaching $41.88. 416,923 shares of the company traded hands, compared to its average volume of 23,119,564. The company has a market capitalization of $248.06 billion, a P/E ratio of 14.00, a price-to-earnings-growth ratio of 2.41 and a beta of 0.71. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.27 and a current ratio of 1.54. Pfizer Inc. has a fifty-two week low of $35.32 and a fifty-two week high of $46.47.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, April 30th. The biopharmaceutical company reported $0.85 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.75 by $0.10. The business had revenue of $13.12 billion during the quarter, compared to the consensus estimate of $13.01 billion. Pfizer had a return on equity of 27.48% and a net margin of 21.31%. The company’s quarterly revenue was up 1.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.77 EPS. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.89 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 10th will be paid a dividend of $0.36 per share. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.44 dividend on an annualized basis and a yield of 3.44%. Pfizer’s dividend payout ratio (DPR) is currently 48.00%.

WARNING: “Pfizer Inc. (PFE) Stake Lowered by Summit Financial Wealth Advisors LLC” was originally reported by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.baseballdailydigest.com/news/2019/05/23/pfizer-inc-pfe-stake-lowered-by-summit-financial-wealth-advisors-llc.html.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Story: What is Net Asset Value (NAV)?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.